Jean Powers

1.8k citations

32 papers · 1.3k indexed · h-index 17

Impact in

Genetics top 5%
- Chronic Lymphocytic Leukemia Research
Oncology top 5%
- Cancer Treatment and Pharmacology
- Viral-associated cancers and disorders

Papers in ⓘ

Oncology 16
- Cancer Treatment and Pharmacology 4
- Colorectal Cancer Treatments and Studies 3
Pulmonary and Respiratory Medicine 15
- Lung Cancer Treatments and Mutations 8

Co-authors: Elizabeth A. Eisenhauer (11 shared papers)C. Tom Kouroukis (5 shared papers)Michael Crump (4 shared papers)Lesley Seymour (14 shared papers)Randy D. Gascoyne (2 shared papers)Frances A. Shepherd (6 shared papers)James R. Wright (4 shared papers)Scott A. Laurie (5 shared papers)
Journals: Journal of Clinical Oncology (10 papers)Blood (2 papers)European Journal of Cancer (2 papers)Annals of Oncology (2 papers)International Journal of Gynecological Cancer (2 papers)
Partner nations: Canada United States Japan

In The Last Decade

Jean Powers

30 papers receiving 1.3k citations

Peers

Countries citing papers authored by Jean Powers

Since Specialization

Citations

This map shows the geographic impact of Jean Powers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean Powers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean Powers more than expected).

Fields of papers citing papers by Jean Powers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean Powers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean Powers. The network helps show where Jean Powers may publish in the future.

Co-authors

The 25 scholars most cited alongside Jean Powers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jean Powers Line = papers co-authored together Jean Powers links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology ·C. Tom Kouroukis, Andrew Belch, Michael Crump, Elizabeth A. Eisenhauer, Randy D. Gascoyne, Ralph M. Meyer, Reinhard Lohmann, Pedro López, Jean Powers, Robert Turner, Joseph M. Connors	2003	215
2	A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150 Annals of Oncology ·Andrew R. Belch, C. Tom Kouroukis, Michael Crump, Laurie H. Sehn, Randy D. Gascoyne, Richard Klasa, Jean Powers, James R. Wright, Elizabeth A. Eisenhauer	2006	126
3	Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology ·Christine I. Chen, C. Tom Kouroukis, Darrell White, Michael Voralia, Edward A. Stadtmauer, A. Keith Stewart, James R. Wright, Jean Powers, Wendy Walsh, Elizabeth A. Eisenhauer	2007	126
4	Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·Simon J. Crabb, Demetris Patsios, Eric E. Sauerbrei, Peter Ellis, Andrew Arnold, Glenwood Goss, Natasha B. Leighl, Frances A. Shepherd, Jean Powers, Lesley Seymour, Scott A. Laurie	2008	118
5	The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group International Journal of Gynecological Cancer ·Brigette Ma, Amit M. Oza, Elizabeth A. Eisenhauer, G. Stanimir, Mark S. Carey, W. Chapman, Eleanor Latta, Kiran Sidhu, Jean Powers, William R. Walsh, Anthony Fyles	2004	117
6	Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology ·Scott A. Laurie, Isabelle Gauthier, Andrew Arnold, Frances A. Shepherd, Peter Ellis, Eric X. Chen, Glenwood D. Goss, Jean Powers, Wendy Walsh, Dongsheng Tu, Jane Robertson, Thomas A. Puchalski, Lesley Seymour	2008	102
7	Effects of single d‐amino acid substitutions on disruption of β‐sheet structure and hydrophobicity in cyclic 14‐residue antimicrobial peptide analogs related to gramicidin S Journal of Peptide Research ·D.L. Lee, Jean Powers, Karin Pflegerl, Michael L. Vasil, Robert E. W. Hancock, Robert S. Hodges	2004	77
8	A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group European Journal of Cancer ·Glenwood Goss, Frances A. Shepherd, Scott A. Laurie, Isabelle Gauthier, Natasha B. Leighl, Eric X. Chen, Ronald Feld, Jean Powers, Lesley Seymour	2008	57
9	A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195 Investigational New Drugs ·Bernhard J. Eigl, Scott North, Eric Winquist, Daygen L. Finch, Lori Wood, Srikala S. Sridhar, Jean Powers, Jennifer Good, Mansi Sharma, Jeremy A. Squire, Jenny Bazov, Tamara Jamaspishvili, Michael Cox, Penelope A. Bradbury, Elizabeth A. Eisenhauer, K. N.	2015	54
10	Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours British Journal of Cancer ·A.R. Abdul Razak, Sébastien J. Hotte, Lillian L. Siu, E X Chen, Hal W. Hirte, Jean Powers, William R. Walsh, L-A. Stayner, A. Laughlin, Veronica Novotny‐Diermayr, Jing Zhu, Elizabeth A. Eisenhauer	2011	52
11	A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172) Leukemia & lymphoma ·C. Tom Kouroukis, Louis A. V. Fernandez, Michael Crump, Neil Chua, Rena Buckstein, Robert Turner, Sarit Assouline, Richard Klasa, Wendy Walsh, Jean Powers, Elizabeth A. Eisenhauer	2011	46
12	A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200 Annals of Oncology ·Quincy Chu, Torsten O. Nielsen, Thierry Alcindor, Abha A. Gupta, Makoto Endo, Angela Goytain, Huimin Xu, Savita Verma, Richard Tozer, Meg Knowling, V. Bramwell, Jean Powers, Lesley Seymour, E. Eisenhauer	2015	41
13	The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group Leukemia & lymphoma ·Matthew D. Seftel, John Kuruvilla, Tom Kouroukis, Versha Banerji, Graeme Fraser, Michael Crump, Rajat Kumar, Haji Chalchal, Muhammad Salim, Rob C. Laister, Susan Crocker, Spencer B. Gibson, M. Toguchi, John F. Lyons, Hao Xu, Jean Powers, Joana Sederias, Lesley Seymour, Annette E. Hay	2016	34
14	Bortezomib in Relapsed or Refractory Waldenström's Macroglobulinemia Clinical Lymphoma & Myeloma ·Christine Chen, C. Tom Kouroukis, Darrell White, Michael Voralia, Edward A. Stadtmauer, A. Keith Stewart, James R. Wright, Jean Powers, Wendy Walsh, Elizabeth A. Eisenhauer	2009	23
15	A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196 Oncotarget ·Natasha B. Leighl, Ming‐Sound Tsao, Geoffrey Liu, Dongsheng Tu, Cheryl Ho, Frances A. Shepherd, Nevin Murray, John R. Goffin, Garth Nicholas, Shingo Sakashita, Zhuo Chen, Lucia Kim, Jean Powers, Lesley Seymour, Glenwood Goss, Penelope A. Bradbury	2017	23
16	Phase 2 study of T138067-sodium in patients with malignant glioma: Trialof the National Cancer Institute of Canada Clinical Trials Group Neuro-Oncology ·Sarah Kirby, S. Gertler, Warren Mason, Christopher Watling, Peter Forsyth, Jacinta Aniagolu, Robert Stagg, Matthew Wright, Jean Powers, Elizabeth A. Eisenhauer	2005	20
17	IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group Journal of Clinical Oncology ·Glenwood Goss, Scott A. Laurie, Frances A. Shepherd, Natasha B. Leighl, E. Chen, Isabelle Gauthier, Neil Reaume, Ronald Feld, Jean Powers, Lesley Seymour	2007	17
18	NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer Journal of Thoracic Oncology ·Peter Ellis, Frances A. Shepherd, Scott A. Laurie, Glenwood D. Goss, Martin Olivo, Jean Powers, Lesley Seymour, Penelope A. Bradbury	2014	16
19	A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy Journal of Clinical Oncology ·K. N., E. Eisenhauer, Ladan Fazli, Edward C. Jones, Jean Powers, D. Ayers, S. Larry Goldenberg, Martin Gleave	2004	14
20	Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214. Journal of Clinical Oncology ·Derek J. Jonker, Sébastien J. Hotte, Albiruni Ryan Abdul Razak, Daniel J. Renouf, Brian D. Lichty, John C. Bell, Jean Powers, Caroline J. Breitbach, David F. Stojdl, Kyle B. Stephenson, Jonathan L. Bramson, Jeff Hummel, Chantal G. Lemay, Jean‐Claude Cutz, Julie Wells, Robin A.J. Eady, Xiaoqun Sun, Dongsheng Tu, Janet Dancey	2017	13

About Jean Powers

Jean Powers is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Genetics and Cancer Research, having authored 32 papers that have together received 1.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (8 papers), Chronic Lymphocytic Leukemia Research (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Cancer Treatment and Pharmacology (4 papers), Lymphoma Diagnosis and Treatment (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Protein Degradation and Inhibitors (3 papers) and Cancer, Lipids, and Metabolism (3 papers). The work is most often cited by research in Genetics (270 citations), Oncology (556 citations), Pathology and Forensic Medicine (356 citations), Obstetrics and Gynecology (101 citations) and Reproductive Medicine (101 citations). Jean Powers has collaborated with scholars based in Canada, United States and Japan. Frequent co-authors include Elizabeth A. Eisenhauer, C. Tom Kouroukis, Michael Crump, Lesley Seymour, Randy D. Gascoyne, Frances A. Shepherd, James R. Wright, Scott A. Laurie, Wendy Walsh and Robert Turner. Their work appears in journals such as Journal of Clinical Oncology, Blood, European Journal of Cancer, Annals of Oncology and International Journal of Gynecological Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact